Depression and Anxiety Trial, Recruiting (NCT07047820)

Depression and Anxiety Trial, Recruiting NCT07047820 Sponsor: Biogen Condition: Depression and Anxiety

Printed from Voxsanity (voxsanity.com.au) — NCT07047820 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Depression And Anxiety

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults who were prescribed zuranolone for postpartum depression (depression following the end of a pregnancy) and had it filled successfully one time through CVS Specialty Pharmacy, between June 2025 and May 2026, within 12 months of the end of their pregnancy.
People who currently live in the United States.
People who are able to complete questionnaires on their own, without assistance.

Who may not be able to join:

People who had zuranolone or brexanolone (a similar medication) filled in the 12 months before joining the trial.
People who have already taken 2 or more doses of zuranolone by the time of their screening for the trial.
People who have been diagnosed with bipolar disorder at any point in their life, or who currently have it.
People who did not complete the required starting surveys before taking their second dose of zuranolone.
People whose pregnancy ended more than 12 months ago.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Medical Director, Biogen

Phone: 866-633-4636

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07047820

Sponsor: Biogen

Phase: Not Applicable

Status: Recruiting

Condition: Depression and Anxiety

Trial contact: 866-633-4636

More information: https://clinicaltrials.gov/study/NCT07047820

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults who were prescribed zuranolone for postpartum depression (depression following the end of a pregnancy) and had it filled successfully one time through CVS Specialty Pharmacy, between June 2025 and May 2026, within 12 months of the end of their pregnancy.
People who currently live in the United States.
People who are able to complete questionnaires on their own, without assistance.

Who may not be able to join:

People who had zuranolone or brexanolone (a similar medication) filled in the 12 months before joining the trial.
People who have already taken 2 or more doses of zuranolone by the time of their screening for the trial.
People who have been diagnosed with bipolar disorder at any point in their life, or who currently have it.
People who did not complete the required starting surveys before taking their second dose of zuranolone.
People whose pregnancy ended more than 12 months ago.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Biogen

Registry

ClinicalTrials.gov

Start date

30 June 2025

Est. completion

24 August 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change From Baseline in Edinburgh Postnatal Depression Scale (EPDS) at Day 15

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov